ArticleRespiratory medicine case reports2017
Immunotherapy "Shock" with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma.
Article in Respiratory medicine case reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 20 citations in OpenAlex.
- Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.Frontiers in oncology · 2023Article
- Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.Frontiers in oncology · 2022Article
- Lung cancer, treatment and nutritional status.Molecular and clinical oncology · 2021Article
- Analysis of tumor response and clinical factors associated with vitiligo in patients receiving anti-programmed cell death-1 therapies for melanoma: A cross-sectional study.JAAD international · 2021Article
- Immune checkpoint inhibitor-related dermatologic adverse events.Journal of the American Academy of Dermatology · 2020Review
- Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: a case report.Translational lung cancer research · 2020Article
- Inhaled chemotherapy adverse effects: mechanisms and protection methods.Lung cancer management · 2020Review
- Acute pneumothorax due to immunotherapy administration in non-small cell lung cancer.Respiratory medicine case reports · 2020Article
- Targeting the PD-1/PD-L1 Axis in Human Vitiligo.Frontiers in immunology · 2020Review
- Sex Differences and Adverse Effects between Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer.Journal of Cancer · 2020Article
- Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Article
- Melanoma and Vitiligo: In Good Company.International journal of molecular sciences · 2019Review
- Treatment Outcomes of Immune-Related Cutaneous Adverse Events.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Article
- Biopsy and rebiopsy for non-small-cell lung cancer: current and future methods.Lung cancer management · 2019Article
- Inhaled Cisplatin for NSCLC: Facts and Results.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effective and safe therapies in comparison to the non-specific cytotoxic agents. Regarding tyrosine kinase inhibitors the adverse effects have been fully explored, however; on the other hand for immunotherapy there are still several issues to be clarified. We report a rare case of a patient with lung cancer adenocarcinoma who developed vitiligo throughout his body after nivolumab administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.